Amgen (AMGN) Cuts 42 Jobs in Zug, Switzerland
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St futures gain on Iran ceasefire hopes; earnings in focus
- Oil prices firm as investors weigh fresh attacks against potential US-Iran ceasefire
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
RBC Thinks Amgen's (AMGN) AMG145 Has 'Compelling' Safety Profile Profile; Sees $10B Market Opportunity
November 7, 2012 10:09 AM ESTAmgen (Nasdaq: AMGN) is lower on the session Wednesday amid positive comments out of RBC for its AMG145 drug.
RBC analyst Michael Yee said that AMG145 -- Amgen's late-stage cardio drug -- will grab investor interest over the next year and out-year consensus... More
